On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash deal valued at approximately $6.7 billion. The move, priced at $53.00 per share, marks the culmination of one of the most dramatic corporate turnarounds in recent biotech history.
Terns, once a mid-tier player in the crowded metabolic space, has spent the last year reinventing itself as a high-conviction oncology powerhouse. Today’s acquisition is not merely a financial exit; it is a strategic validation of Terns’ pivot toward next-generation cancer therapies, specifically its potential best-in-class treatment for chronic myeloid leukemia (CML). As the dust settles on the merger announcement, TERN stands as a prime example of how scientific focus and agile management can create massive shareholder value in a volatile market.
Historical Background
Terns Pharmaceuticals was founded in 2017 with a pedigree that immediately commanded Wall Street’s attention. The company was launched by a team of industry veterans, many hailing from Eli Lilly and Company (NYSE: LLY), and backed by a $30 million Series A led by Lilly Asia Ventures. Its founding mission was to combat the global epidemic of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH.
In its early years, Terns operated under a "hub-and-spoke" model, acquiring small-molecule programs from Eli Lilly and utilizing a lean development strategy. The company went public in early 2021 at $17.00 per share, riding the wave of investor interest in metabolic health. However, like many of its peers, Terns faced the "biotech winter" of 2022-2023, during which it struggled with high development costs and a shifting regulatory landscape for liver disease. The company's original focus on MASH and obesity provided several early milestones, but it wasn't until the strategic leadership shift in 2024 that the seeds for today's multibillion-dollar acquisition were truly sown.
Business Model
Until late 2025, Terns Pharmaceuticals operated as a clinical-stage biopharmaceutical company focused on small-molecule drugs for metabolic diseases and oncology. Its revenue model was pre-commercial, relying entirely on capital markets, strategic partnerships, and potential milestone payments.
However, in August 2025, Terns executed a radical shift in its business model. Following a strategic review, the company transitioned into a "pure-play oncology" entity. Under this new model, Terns concentrated its internal R&D capital exclusively on its oncology pipeline, led by TERN-701. Its legacy metabolic assets, including its oral GLP-1 receptor agonist (TERN-601) and its THR-β agonist (TERN-501), were shifted to a "partner-funded" model. This lean approach allowed the company to preserve cash and focus all technical resources on the highest-value clinical targets, a move that eventually made them an irresistible target for Merck.
Stock Performance Overview
The stock performance of TERN has been a tale of two extremes. Since its 2021 IPO at $17.00, the stock experienced a prolonged decline, hitting a "dark period" in late 2024 and early 2025 when it traded as low as $1.80 per share. This 90% decline from its peak was driven by concerns over the competitiveness of its oral GLP-1 candidate and the general exit of capital from small-cap biotech.
The recovery began in late 2025 following the release of groundbreaking clinical data at the American Society of Hematology (ASH) annual meeting. In the final quarter of 2025, TERN shares staged a 1,000% recovery, climbing from penny-stock territory back to the mid-$20s as investors realized the potential of TERN-701. Today’s acquisition price of $53.00 per share represents a 211% premium over its 2021 IPO price and a staggering 2,800% return for investors who had the foresight to buy during the 2025 lows.
Financial Performance
Prior to the Merck acquisition announcement, Terns reported a significantly strengthened balance sheet. As of the end of 2025, the company held approximately $1.0 billion in cash and marketable securities, following a series of successful secondary offerings triggered by positive clinical data.
In its last quarterly report, Terns showed a net loss consistent with its status as a clinical-stage firm, with R&D expenses totaling roughly $45 million per quarter. However, the company’s "cash runway" was projected to extend into 2031, providing it with an unusually strong negotiating position. This financial independence meant Terns did not need to sell, allowing it to command a significant premium from Merck, which is looking to deploy its massive cash reserves to shore up its portfolio ahead of the 2028 patent cliff for Keytruda.
Leadership and Management
The architect of Terns’ transformation is CEO Amy Burroughs, who took the helm in early 2024. Burroughs replaced the founding leadership during a period of corporate stagnation and is widely credited with the "oncology-first" pivot. Alongside CFO Andrew Gengos, Burroughs successfully navigated the company through the treacherous waters of 2025, balancing clinical risk with fiscal discipline.
The board of directors, led by Chairman David Fellows and including former Pfizer CEO Jeffrey Kindler, provided the governance necessary to execute a major strategic pivot without losing institutional support. The leadership team’s reputation for transparency and "failing fast" on lower-potential assets (like the internal GLP-1 program) built the credibility required to secure the multi-billion dollar valuation announced today.
Products, Services, and Innovations
The "crown jewel" of the Terns portfolio is TERN-701, an oral, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML). Unlike traditional TKIs that bind to the orthosteric site of the BCR-ABL protein, TERN-701 binds to the allosteric myristoyl pocket. This mechanism allows it to maintain activity against mutations that cause resistance to first- and second-generation therapies.
In Phase 1 CARDINAL data released in late 2025, TERN-701 demonstrated a Major Molecular Response (MMR) rate of 64%–75% in heavily pre-treated patients. Crucially, the drug showed no significant drug-drug interactions and lacked the fasting requirements associated with its primary competitor, Novartis’ Scemblix (asciminib). Terns’ metabolic legacy lives on in TERN-501 (a THR-β agonist) and TERN-601 (oral GLP-1), though these are now expected to be developed by Merck or further out-licensed to other partners.
Competitive Landscape
In the oncology space, Terns’ primary rival is Novartis (NYSE: NVS), whose drug Scemblix currently dominates the allosteric CML market. Terns has positioned TERN-701 as a "best-in-class" successor, citing a more favorable safety profile and easier dosing (no food effect).
In the now-secondary metabolic segment, Terns had faced insurmountable competition from giants like Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). The decision to "mothball" internal development of TERN-601 in late 2025 followed disappointing Phase 2 results that showed the drug was unlikely to beat Lilly’s orforglipron on efficacy or safety. By exiting this "arms race," Terns avoided a potentially ruinous capital drain, focusing instead on the less-crowded but high-value CML niche.
Industry and Market Trends
Today’s acquisition reflects a broader trend in the biopharma industry: the "flight to quality." Large pharmaceutical companies are increasingly looking for de-risked assets with clear "best-in-class" potential to offset upcoming revenue losses from patent expirations.
Furthermore, the rise of allosteric inhibitors—drugs that target a protein away from its active site—is a major trend in precision oncology. TERN-701 is at the forefront of this wave. In the metabolic sector, the trend has shifted toward multi-agonist therapies (GLP-1/GIP/GCG), making small-molecule mono-therapies like TERN-601 less attractive to investors unless they show extraordinary potency.
Risks and Challenges
Despite the successful buyout, the path for Terns was not without significant risk. The Phase 2 FALCON trial for TERN-601 in 2025 showed Grade 3 liver enzyme elevations in some patients, a setback that could have sunk the company had it not already been diversifying into oncology.
For Merck, the challenge now lies in the "pivotal" transition. TERN-701 must still pass through Phase 3 trials and secure FDA approval before it can generate revenue. Any safety signals that emerge in larger patient populations could significantly devalue the $6.7 billion investment. Furthermore, the integration of a small, agile biotech culture into a global giant like Merck always carries the risk of losing scientific momentum.
Opportunities and Catalysts
The immediate catalyst for Terns shareholders is the cash payout, but for the broader market, the focus shifts to the upcoming Phase 3 trials of TERN-701 under Merck’s leadership. Merck has the global infrastructure and commercial expertise to accelerate the drug’s development and potentially expand its use into first-line CML treatment.
Additionally, Merck now has the option to re-invigorate Terns' metabolic pipeline. With the deep pockets of a Big Pharma parent, the TERN-601 and TERN-501 programs could be reformulated or combined with Merck’s existing internal candidates to create a new metabolic franchise, providing "hidden value" beyond the oncology headline.
Investor Sentiment and Analyst Coverage
Sentiment around Terns shifted from "cautious" to "bullish" in December 2025. Following the ASH data, major firms including Mizuho and TD Cowen upgraded the stock to "Strong Buy" with price targets in the $40–$50 range. Institutional ownership had surged to over 90% by early 2026, with major positions held by BlackRock and Vivo Capital.
On retail platforms, Terns became a "comeback kid" story, frequently cited as an example of how a clinical setback in one area (metabolic) does not necessarily invalidate a company's entire platform. Today’s merger announcement has been met with widespread acclaim from analysts who see it as a "perfect fit" for Merck’s portfolio.
Regulatory, Policy, and Geopolitical Factors
The regulatory environment for TERN-701 has been highly favorable. The FDA granted the drug Fast Track designation in late 2025, acknowledging the unmet need for resistant CML patients. This designation will allow for a rolling review of the New Drug Application (NDA), potentially shortening the time to market.
Geopolitically, Terns’ historical ties to Lilly Asia Ventures and its early operations in China were once a point of concern for some investors due to trade tensions. However, by shifting its operational focus entirely to U.S.-based oncology clinical trials, Terns mitigated much of the geopolitical risk associated with cross-border biotech collaborations.
Conclusion
The acquisition of Terns Pharmaceuticals by Merck on this March 25, 2026, marks the end of an era for the company and the beginning of a high-stakes clinical journey for its lead asset. For investors, the TERN story is a masterclass in strategic adaptability. By recognizing the limitations of its metabolic pipeline and doubling down on a differentiated oncology asset, the management team turned a $2.00 stock into a $53.00 payout in less than 18 months.
While Terns as an independent entity will soon cease to exist, its scientific contributions—particularly in the realm of allosteric inhibition—are likely to have a lasting impact on the treatment of leukemia. For the broader market, this deal signals that even in a top-heavy industry, there is still immense value to be found in clinical-stage biotech for those willing to look past short-term volatility.
This content is intended for informational purposes only and is not financial advice. As of March 25, 2026, Terns Pharmaceuticals is slated to be acquired by Merck & Co. Investors should consult with a financial advisor before making any investment decisions.